OBJECTIVE

To study the safety and efficacy of Relatox in correction of platysmal bands.

MATERIAL AND METHODS

A multicenter prospective randomized trial was performed between 2020 and 2022. We analyzed efficacy and safety of Relatox in correction of platysmal bands. There were 188 patients aged 35—64 years (mean 50.18±8.69). Relatox injections were performed in 94 patients (10 men and 84 women), placebo injections – in the same number of patients (7 men and 87 women). The study took place in two stages. At the first stage, we assessed efficacy of Relatox in patients with platysmal bands VDPBS score 2 and 3 (moderate-to-severe). After confirming the efficacy and safety of Relatox, patients with platysmal bands VDPBS score 3 and 4 (severe and very severe) were included in the study. At the first stage, Relatox was injected into platysmal bands at 4—7 points located at a distance of 2—3 cm from each other (1—3 units per a point). At the second stage, we injected Relatox at 4—12 points (1—5 units depending on severity of platysmal bands). Efficacy and safety were evaluated using photographing, VDPBS and GAIS scales. Doctors recorded all adverse events

RESULTS

There was significant (p<0.001) decrease of VDPBS scores and improvement in appearance according to the GAIS scale after Relatox injections. The number of local and systemic adverse events was insignificant and did not differ in both groups (p>0.809, Fisher's test). No major adverse events were identified. There were no significant deviations of laboratory parameters in both groups.

CONCLUSION

Our data indicate the safety and efficacy of Relatox for correction of platysmal bands.